Search Results

You are looking at 191 - 200 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Oncology Research Program

shown to have a 14% response rate in angiosarcomas in previously treated patients in the phase II setting. Bevacizumab has demonstrated a 12% response rate. Given the limited data on the activity of pazopanib in angiosarcomas, the investigators propose

Full access

Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease

Manish A. Shah and David P. Kelsen

encouraging in phase II evaluation ( Table 6 ). The initial study of irinotecan, cisplatin, and bevacizumab was instrumental in developing this class of targeted therapy in this disease. Concerns about using antiangiogenic agents stem from the risk for upper

Full access

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania

advanced gastrointestinal tract NETs. 28 , 62 – 64 In a recent large randomized study led by SWOG, treatment with interferon alfa-2b was compared with bevacizumab in 427 patients with progressive NETs. 65 Octreotide was included in both arms of this study

Full access

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, James Stevenson, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

cisplatin. 96 – 98 Data also show that first-line therapy with gemcitabine plus pemetrexed is effective, although this regimen is toxic (grade 3–4 neutropenia, 60%). 99 A phase II trial assessed atezolizumab plus bevacizumab as subsequent therapy for 20

Full access

Thymoma Versus Thymic Carcinoma: Differences in Biology Impacting Treatment

Ronan J. Kelly

evidence of EGFR or KRAS mutations. A second phase II trial evaluated the efficacy and safety of the combination of erlotinib and bevacizumab in 18 (thymoma, 11; thymic carcinoma, 7) pretreated patients with progressive malignant thymic tumors. Standard

Full access

Rectal Cancer, Version 2.2015

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass

investigator's discretion. 15 No differences were seen in clinical outcomes, but the group receiving induction therapy experienced higher toxicity. The single-arm phase II AVACROSS study assessed the safety and efficacy of adding bevacizumab to induction

Full access

Risk Assessment and Prophylaxis for VTE in Cancer Patients

Alok A. Khorana

VTE when given in combination with dexamethasone or chemotherapy. Bevacizumab-containing regimens have been associated with increased risk for an arterial thromboembolic event (hazard ratio [HR], 2.0; 95% CI, 1.05-3.75), but the data on VTE risk are

Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

from a phase III randomized trial (GOG 0218) assessing bevacizumab combined with carboplatin/paclitaxel in the up-front setting compared with carboplatin/paclitaxel alone. Although data regarding overall survival and/or quality of life have not been

Full access

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

durations. 123 A more recent study of patients (n=420) with HER2-negative, advanced breast cancer showed that intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment. The median overall PFS for intermittent

Full access

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, Shaili Aggarwal, and Sara Espinosa

-based chemotherapy (cisplatin or carboplatin)/paclitaxel/bevacizumab has been extensively investigated in clinical studies, and these combinations are among the preferred, first-line treatment options for patients with recurrent/metastatic cervical cancer in the NCCN